Abstract
Alzheimer disease (AD) is characterized by a progressive cognitive decline and accumulation of β-amyloid (Aβ) forming senile plaques that are associated with inflammatory molecules and cells. Resident microglia and newly differentiated cells that are derived from the bone marrow are found in the vicinity of Aβ plaques. Although these two types of microglia are not distinguishable by specific markers in the brain, they seem to possess different phenotype and functions. In mouse models of AD, bone marrow-derived microglia (BMDM) have been shown to delay or stop the progression of AD and preventing their recruitment exacerbates the pathology. Transplantation of competent hematopoietic stem cells or their genetic modifications ameliorate cognitive functions, reduce Aβ accumulation and prevent synaptic dysfunctions. Improving the recruitment of genetically-modified BMDM may be considered as a powerful new therapeutic strategy to counteract AD. Here we review the role of microglia subsets in AD and how these cells have a great potential to fight against Aβ accumulation and cognitive impairment.
Keywords: Microglia, Alzheimers disease, CCR2, CX3CR1, Inflammation, Innate immunity, Cytokines, Chemokines
Current Alzheimer Research
Title: The Role of Microglial Cell Subsets in Alzheimers Disease
Volume: 8 Issue: 2
Author(s): G. Naert and S. Rivest
Affiliation:
Keywords: Microglia, Alzheimers disease, CCR2, CX3CR1, Inflammation, Innate immunity, Cytokines, Chemokines
Abstract: Alzheimer disease (AD) is characterized by a progressive cognitive decline and accumulation of β-amyloid (Aβ) forming senile plaques that are associated with inflammatory molecules and cells. Resident microglia and newly differentiated cells that are derived from the bone marrow are found in the vicinity of Aβ plaques. Although these two types of microglia are not distinguishable by specific markers in the brain, they seem to possess different phenotype and functions. In mouse models of AD, bone marrow-derived microglia (BMDM) have been shown to delay or stop the progression of AD and preventing their recruitment exacerbates the pathology. Transplantation of competent hematopoietic stem cells or their genetic modifications ameliorate cognitive functions, reduce Aβ accumulation and prevent synaptic dysfunctions. Improving the recruitment of genetically-modified BMDM may be considered as a powerful new therapeutic strategy to counteract AD. Here we review the role of microglia subsets in AD and how these cells have a great potential to fight against Aβ accumulation and cognitive impairment.
Export Options
About this article
Cite this article as:
Naert G. and Rivest S., The Role of Microglial Cell Subsets in Alzheimers Disease, Current Alzheimer Research 2011; 8 (2) . https://dx.doi.org/10.2174/156720511795256035
DOI https://dx.doi.org/10.2174/156720511795256035 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Stem Cells in Brain Tumorigenesis and their Impact on Therapy
Current Stem Cell Research & Therapy Generation of Mesenchymal Stem Cells by Blood Cell Reprogramming
Current Stem Cell Research & Therapy Predicting the Potential Public Health Impact of Disease-Modifying HIV Vaccines in South Africa: The Problem of Subtypes
Current Drug Targets - Infectious Disorders Microglial Activation in Alzheimers Disease
Current Alzheimer Research Update on ICOS: A Possible Target for Turning-Off Autoimmunity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Neuroinflammation: Microglial Activation During Sepsis
Current Neurovascular Research Protein Kinase CK2 in Human Diseases
Current Medicinal Chemistry CC Chemokine Receptor Small Molecule Antagonists in the Treatment of Rheumatoid Arthritis and Other Diseases: A Current View
Current Topics in Medicinal Chemistry Opiate Drug Use and the Pathophysiology of NeuroAIDS
Current HIV Research Potential Use of Nanomedicine for Drug Delivery Across the Blood-Brain Barrier in Healthy and Diseased Brain
CNS & Neurological Disorders - Drug Targets Safety of Systemic Biologic Agents in the Treatment of Non-malignant Skin Disorders
Current Drug Safety Base Distribution in Dengue Nucleotide Sequences Differs Significantly from Other Mosquito-Borne Human-Infecting Flavivirus Members
Current Computer-Aided Drug Design Implications of Prion Protein Biology
Current Neurovascular Research HIV-1 Induced CNS Dysfunction: Current Overview and Research Priorities
Current HIV Research Nanomaterials’s Effect on Polymerase Chain Reaction
Current Nanoscience CT and MR Imaging of the Encephalopathic Child
Current Medical Imaging Recent Advances in Flavivirus Antiviral Drug Discovery and Vaccine Development
Recent Patents on Anti-Infective Drug Discovery The Antitumor Effects of Icaritin Against Breast Cancer is Related to Estrogen Receptors
Current Molecular Medicine Nanomaterials-based Polymerase Chain Reactions for DNA Detection
Current Organic Chemistry Recent Patents on Nucleic Acid-Based Antiviral Therapeutics
Recent Patents on Anti-Infective Drug Discovery